Hepatitis C News and Research

Latest Hepatitis C News and Research

Anesthetist may have infected patients during procedure

There has been a breach in the strict infection prevention protocols followed by health care staff including doctors presumably by an Anesthetist. Nearly 250 patients in Western Australia might have been already infected with HIV, Hepatitis B and C and syphilis.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

Idenix Pharmaceuticals prices underwritten offering of common stock at $4.35 per share

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten offering of 6,460,672 shares of its common stock at a price of $4.35 per share. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $26.2 million. All of the shares are being sold by Idenix.

29 Apr 2010

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.

29 Apr 2010

PAF annual report offers summary of issues impacting Americans' access to healthcare

Patient Advocate Foundation -- a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases -- today released their annual Patient Data Analysis Report, which documents the scope and complexity of the healthcare finance, access and job retention issues routinely confronted by patients at the national and state-specific level.

29 Apr 2010

Study examines lifestyle-related causes of death in AIDS patients

The study, by researchers from the University of Bristol and a large group of international collaborators, examined data from the Antiretroviral Therapy Cohort Collaboration (ART-CC) which involved nearly 40,000 patients who started ART between 1996 and 2006 in Europe and North America.

29 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

FDHN announces 2010 AGA Research Scholars

The Foundation for Digestive Health and Nutrition has announced the 2010 American Gastroenterological Association Foundation research scholars. The grants have been awarded to seven outstanding young gastroenterologists who promise to make significant strides in the field of gastrointestinal research.

28 Apr 2010

Causes of death in AIDS patients

New research shows that Antiretroviral Therapy (ART) continues to dramatically reduce rates of mortality from HIV infection in high-income countries, such that non-AIDS-related deaths exceed AIDS deaths after approximately four years of taking ART.

28 Apr 2010

ChronSeal multi-center study in Sweden and Norway finalized

The multi-center study in Sweden and Norway with ChronSeal® is now finalized and the data are being analyzed in Sweden and by Kringle in Japan. ChronTech and Kringle have jointly decided that the results will be publicly available on May 27th. At follow-up of the ChronVac-C® -study where patients now have started treatment according to standard-of-care (interferon and ribavirin) all patients (100%) were virus free at treatment week 12 and 5/6 (83%) had less than 50 copies of virus/mL blood already at treatment week four.

28 Apr 2010

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

Biostar Pharmaceuticals, Inc., the Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsule, and other pharmaceutical products, announced today it has received new advertising approval from Shaanxi State Food and Drug Administration for marketing Xin Aoxing Oleanolic Acid Capsules.

27 Apr 2010

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.

27 Apr 2010

Scientists develop rapid point-of-care diagnostic test to measure CD4 T-cells

Scientists at Australia's Burnet Institute have developed a rapid point-of-care diagnostic test for the measurement of CD4 T-cells, a marker of the immune system for people living with HIV and AIDS.

27 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

Nanoviricides become registered trademark under USPTO

NanoViricides, Inc., announced today that the mark "nanoviricides" has now become a registered trademark under the US Patents and Trademarks Office. The mark was entered into the "principal register" of trademarks at the USPTO on April 20, 2010.

26 Apr 2010

Federal allocation not adequately addressing needs of minority AIDS community

The Joint Center for Political and Economic Studies Health Policy Institute will unveil a study "Following the Money: Tracking Federal AIDS Appropriations to Address Disparities in HIV and AIDS Treatment in the United States." The study looks at funds and resources provided under the Ryan White Act and concludes that the allocation does not adequately address the needs of the minority AIDS community and fails to reflect the rapid rise in AIDS infection rates in rural, Southern communities, which are primarily African American communities.

26 Apr 2010

Presidio Pharmaceuticals, Numerate conclude collaboration to discover new compounds targeting HCV

Presidio Pharmaceuticals, Inc., and Numerate, Inc., today announced that they have concluded their two-year collaboration to discover new compounds that target hepatitis C virus (HCV).

24 Apr 2010

Biostar Pharmaceuticals lists on NASDAQ Global Market

Biostar Pharmaceuticals, Inc., a Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced that the Company was approved by NASDAQ to list its common stock on the NASDAQ Global Market. The Company's listing application was reviewed and approved by NASDAQ's Listing Qualifications Department for compliance with all of NASDAQ's standards.

23 Apr 2010

Human lymphocytes produce hepcidin that regulate iron levels in the body: Study

For some years now a small group of scientists have been pioneering a revolutionary idea - that the vertebrate immune system could have a role in the regulation of iron in the body. And now, a work soon to be published in the journal Immunology, shows that human lymphocytes (white blood cells) actually produce hepcidin, the most important protein in the regulation of iron levels in the body.

22 Apr 2010

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Interest in cancer prevention is increasing as scientists continue to learn new information and confirm what was already suspected.

22 Apr 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Anesthetist may have infected patients during procedure

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Idenix Pharmaceuticals prices underwritten offering of common stock at $4.35 per share

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

PAF annual report offers summary of issues impacting Americans' access to healthcare

Study examines lifestyle-related causes of death in AIDS patients

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

FDHN announces 2010 AGA Research Scholars

Causes of death in AIDS patients

ChronSeal multi-center study in Sweden and Norway finalized

Biostar receives Shaanxi SFDA approval to market Xin Aoxing Oleanolic Acid Capsules

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

Scientists develop rapid point-of-care diagnostic test to measure CD4 T-cells

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Nanoviricides become registered trademark under USPTO

Federal allocation not adequately addressing needs of minority AIDS community

Presidio Pharmaceuticals, Numerate conclude collaboration to discover new compounds targeting HCV

Biostar Pharmaceuticals lists on NASDAQ Global Market

Human lymphocytes produce hepcidin that regulate iron levels in the body: Study

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in